Successful alpha‐2b‐interferon therapy for chronic neutrophilic leukemia
Authors:
- 1 August 1993
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 43 (4) , 307-309
Abstract
The authors report two patients with characteristic features of chronic neutrophilic leukemia (CNL) treated with alpha‐2b‐interferon (IFN) (Schering‐Plough). At initiation of therapy, both patients had progressive disease and presented with large tumors. A rapid reduction of the tumor mass and a long‐term stabilisation of the myeloproliferative disorder was obtained (therapy duration 16 and 26 months, respectively, and presently ongoing). In one patient, the dose of IFN could be significantly reduced during maintenance without relapse. Neither presented infectious or hemorrhagic complications under therapy. Alpha‐2b‐interferon is active and safe in CNL, even pretreated and progressive. It can also correct the neutrophil and natural killer functional defects frequently observed in CNL.Keywords
This publication has 8 references indexed in Scilit:
- Neutrophil Function in Chronic Neutrophilic Leukemia: Defective Respiratory Burst in Response to Phorbol EstersActa Haematologica, 1992
- CHRONIC NEUTROPHILIC LEUKAEMIA ASSOCIATED WITH POLYCYTHEMIA VERA: PATHOGENETIC IMPLICATIONS AND THERAPEUTIC APPROACHBritish Journal of Haematology, 1991
- Chronic neutrophilic leukemia and multiple myeloma: An association with λ light chain expressionCancer, 1990
- Alpha Interferon for Induction of Remission in Hairy-Cell LeukemiaNew England Journal of Medicine, 1984
- Chronic neutrophilic leukaemia with enlarged lymph nodes and lysozyme deficiencyJournal of Clinical Pathology, 1983
- Functional characterization of the cells in chronic neutrophilic leukemiaAmerican Journal of Hematology, 1982
- Chronic Neutrophilic Leukemia: Report of Two Cases and Review of the LiteratureAmerican Journal of Clinical Pathology, 1979
- Neutrophilic LeukemiaAnnals of Internal Medicine, 1974